Article Text
Abstract
Neuropathic pain (NP) develops as a consequence of a lesion or disease affecting the somatosensory pathways in the peripheral or central nervous system, and occurs in many neurological diseases (eg, peripheral neuropathy, radiculopathy, spinal cord injury, stroke and multiple sclerosis). It affects 6%–8% of the general population and its impact on quality of life, mood and sleep exceeds the burden of its causative pathology. A peculiar feature of NP is the coexistence of negative and positive symptoms and signs, reflecting loss-of-function and gain-of-function of the somatosensory system, respectively. NP has long been considered a difficult clinical issue because of the lack of a diagnostic gold standard and the unsatisfactory response to treatment. In recent years, a redefinition, diagnostic algorithm, and some guidelines on diagnosis and treatment of NP have been published. This review offers an updated overview on the definition, pathophysiology, clinical evaluation, diagnosis and treatment of NP and focuses on some of the most frequent NP conditions. We intend to help overcome uncertainties on NP and bridge the gap between evidence based medicine and the real clinical world.
- Neuropathic pain
- Diagnosis
- Treatment
- Assessment
- Pathophysiology
Statistics from Altmetric.com
Linked Articles
- Editors' choice
Read the full text or download the PDF:
Other content recommended for you
- Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic
- Integrating mechanistic-based and classification-based concepts into perioperative pain management: an educational guide for acute pain physicians
- Diagnosis and management of neuropathic pain
- An update on the drug treatment of neuropathic pain. Part 1: antidepressants
- An update on the drug treatment of neuropathic pain. Part 2: antiepileptics and other drugs
- Non-inferiority double-blind randomised controlled trial comparing gabapentin versus tramadol for the treatment of chronic neuropathic or mixed pain in children and adolescents: the GABA-1 trial—a study protocol
- Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study
- Neuropathic pain in children
- Drug treatment of neuropathic pain
- Neuropathic pain treatment and research: experiences from the United Kingdom mission to Afghanistan and future prospects